BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to “Market Perform” from “Outperform” and cut its price target to $64, saying the Danish drugmaker’s early lead in the obesity drug market is ...

Eli Lilly's (LLY) stock surges 14% as its diabetes drug orforglipron meets Phase 3 goals, cutting weight by 8%. Read more ...